Late-stage Lyme disease is the most advanced form of Lyme infection, developing weeks to months (and sometimes years) after an untreated or inadequately treated tick bite. It occurs when Borrelia burgdorferi bacteria spread from the initial bite site into joints, the nervous system, the heart, and skin. The most common features are recurring arthritis in large joints, cognitive problems like memory loss, and nerve pain or tingling in the hands and feet.
How Late-Stage Lyme Develops
Lyme disease progresses through stages. Early localized disease typically produces the well-known bull’s-eye rash within days of a tick bite. If left untreated, the bacteria disseminate through the bloodstream into tissues throughout the body. Late-stage disease can appear anywhere from a few weeks to over a decade after the original infection.
The bacteria are unusually skilled at hiding from the immune system. They alter the proteins on their outer surface to avoid detection, and they gravitate toward collagen-rich tissues like tendons, ligaments, and the connective tissue around the heart. These are environments where immune cells have a harder time reaching them. Even when the immune system does mount a response, the resulting inflammation can itself cause significant tissue damage, which is part of why symptoms can be so persistent and widespread.
Joint Pain and Lyme Arthritis
Lyme arthritis is the single most recognizable feature of late-stage disease. It accounts for roughly one in four Lyme cases reported to the CDC. The knees are affected most often, but shoulders, ankles, elbows, wrists, hips, and even the jaw can be involved. The pattern is typically intermittent: a joint swells dramatically, stays painful for days to weeks, then partially or fully calms down before flaring again.
In children, Lyme arthritis can closely mimic juvenile rheumatoid arthritis, particularly the form that affects only a few joints. This resemblance sometimes delays the correct diagnosis, especially when there’s no recalled tick bite or rash in the child’s history.
Neurological Effects
Late-stage Lyme can affect both the brain and peripheral nerves. The most common neurological pattern is a subtle but disruptive encephalopathy, a mild impairment of brain function. In a landmark study published in the New England Journal of Medicine, 89% of patients with chronic neurological Lyme disease had this encephalopathy, characterized by memory loss, mood changes, and sleep disturbance. The onset ranged from one month to 14 years after initial infection.
The cognitive symptoms are often described as “brain fog,” but they’re more specific than that label suggests. Patients frequently have trouble finding words mid-sentence. Depression is common, affecting roughly a third of patients in that study, with some severe enough to require psychiatric treatment. Extreme irritability is another hallmark: people describe becoming disproportionately angry at situations they would have previously brushed off. Excessive daytime sleepiness rounds out the picture.
Peripheral nerve damage shows up as tingling, numbness, or shooting pains in the hands and feet. Electrophysiological testing in these patients typically reveals damage to the nerve fibers themselves rather than to their insulating coating, a distinction that matters because it affects how quickly nerves can recover. Facial palsy, where one or both sides of the face droop, can also occur, and it’s one of the more common presentations in children with late-stage disease.
Heart and Skin Involvement
Lyme carditis, where the bacteria interfere with the heart’s electrical signaling, can cause palpitations, an irregular heartbeat, dizziness, or shortness of breath. In serious cases the heart’s electrical signals are partially or fully blocked, which can require temporary monitoring in a hospital setting.
A skin condition called acrodermatitis chronica atrophicans is a late manifestation seen primarily in European Lyme disease cases. It begins as a slowly expanding reddish-blue discoloration and swelling, usually on the hands, feet, or other extremities. Over time, if untreated, the skin thins and becomes wrinkled, with prominent veins showing through. In a large study of nearly 700 patients in Slovenia, about 71% had noticeable redness, 55% had bluish discoloration, and close to 59% showed at least one sign of skin atrophy. This condition is rare in North America because the specific Borrelia species that causes it is found almost exclusively in Europe.
How Late-Stage Lyme Is Diagnosed
Diagnosis relies on a combination of clinical symptoms and a two-tier blood test. The first tier is a screening antibody test. If that comes back positive or borderline, a second, more specific test called an immunoblot is run to confirm. For the IgG immunoblot (the type relevant to late-stage disease), at least 5 out of 10 specific bacterial proteins must be detected for a positive result.
One important nuance: by the time late-stage disease develops, IgM results (the antibodies associated with early infection) are no longer reliable. The CDC specifically discourages interpreting IgM results for anyone whose symptoms have lasted longer than 30 days, because false positives become increasingly likely. For late-stage Lyme, only IgG antibody results are considered meaningful. Those IgG antibodies can remain detectable for months to years after the infection has been treated, so a positive blood test alone doesn’t confirm active disease. Doctors diagnose late-stage Lyme by matching the antibody results with the right clinical picture.
Treatment and Recovery
Late-stage Lyme disease is treated with antibiotics, typically for two to four weeks. Oral doxycycline is the standard for Lyme arthritis, while neurological involvement may be treated with either oral doxycycline or intravenous antibiotics, depending on severity. Current European guidelines recommend 14 to 28 days of treatment, though there’s ongoing debate about whether longer courses offer any additional benefit.
The good news is that treatment outcomes for Lyme arthritis are generally strong. In clinical trials, 30 days of oral antibiotics led to complete resolution of arthritis in about 90% of patients within three months. A small percentage of patients continue to have joint inflammation after completing both oral and intravenous courses. These cases often respond to anti-inflammatory medications or, rarely, a surgical procedure to remove the inflamed joint lining.
Neurological recovery tends to be slower and less predictable than joint recovery. Memory problems, fatigue, and nerve pain can take months to improve, and some patients retain residual symptoms even after successful bacterial clearance.
Late-Stage Lyme vs. Post-Treatment Lyme Disease Syndrome
These two conditions are frequently confused, but they’re clinically distinct. Late-stage Lyme disease is an active, ongoing infection that hasn’t been adequately treated. It produces objective findings: swollen joints, abnormal nerve conduction, inflammatory markers in spinal fluid. It responds to antibiotics.
Post-Treatment Lyme Disease Syndrome (PTLDS) refers to lingering symptoms of fatigue, body aches, and cognitive difficulty that persist after a full course of antibiotics. The cause is currently unknown, but the CDC notes that it does not appear to represent an ongoing bacterial infection. One leading hypothesis is that the body’s immune response, originally triggered by the bacteria, continues to produce inflammation even after the bacteria are gone. Lipoproteins shed by the bacteria may drive a prolonged inflammatory state that accounts for the fatigue and pain patients experience.
The distinction matters because PTLDS does not respond to additional rounds of antibiotics, while untreated late-stage Lyme disease does. If you’ve completed antibiotic treatment and your symptoms persist, your doctor will work to distinguish between residual immune-mediated inflammation and the possibility that the initial treatment was insufficient.